GeneQuantum Healthcare
- Biotech or pharma, therapeutic R&D
GeneQuantum (GQ) has developed a strong pipeline of next-gen of XDCs with wider therapeutic window & higher affordability with its proprietary One-Enzyme-One-Reaction bioconjugation technology (DAR2/4/6/8, super stable both in circulation and in storage in liquid form, ADCC depletion w/o Fc engineering, ADCs manufactured in mAb facility, dual payload pADCs, RDCs, and AOCs, etc.) with 4 clinical programs including 1 currently in registration trial in China.
Strategic Collaborations:
Biohaven: out licensed the global right of GQ1011 (FIC anti-FGFR3 ADC )
Biohaven: long term strategic collaboration to develop ADCs on multi-targets
AimedBio: long term strategic collaboration to develop ADCs on multi-targets
Pyramid: out licensed the ex-China right of GQ1010 (anti-TROP2 ADC)
Due to time constraints, we will respectfully decline meetings with CDMOs, CROs and other vendors.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}